

**BAA 14-004 (HSHQDC-14-R-B0008)  
Amendment 1**

June 23, 2014

**QUESTIONS**

1) A TIN (Taxpayer ID No.) is required as part of the registration process but we are not yet incorporated in the U.S. therefore they do not yet have a TIN. Does this make us ineligible to submit a proposal? Do they have to be in compliance with the HSAR 3052.209-70 Prohibition on Contracts with Corporate Expatriates Clause?

**No, you would not be ineligible however please note the following items which require you to be eligible for an award:**

- a) **Registration in SAM (Systems for Award Management, see FAR 52.204-7) is required prior to you being eligible for award consideration unless an exception in FAR 4.1102 applies.**
- b) **You must be in compliance with DHS HSAR Clause HSAR 3052.209-70 "Prohibition on Contracts with Corporate Expatriates."**

2) Is this a follow-on requirement? If so, could you please provide the incumbent contract number for this opportunity? If not, is this a new requirement?

**This is a new requirement, not a follow-on effort.**

3) Page 16 of this BAA on Peptide Array Host-based Diagnostics for Detection of Human Exposure to Biological Agents states: The due date for receipt of Full Proposals is 4:30 P.M. (Local Eastern Time) on 05 May, 2014. Full Proposals WILL NOT BE ACCEPTED after the published due date. This appears to conflict with the information on the cover page and page 24 that lists June 27 as the deadline. Can you clarify?

**The date on page 16 is incorrect. The timeline for submission of proposals is June 27.**

4) Also, with respect to the assays/platforms to be evaluated, have these already been identified and will be provided to researchers or are the assays/platforms expected to be in the hands of the proposers? Are you looking for people who already have assays or for people who have the skills to design and conduct an evaluation of existing array technologies?

**The Government will not provide arrays or platforms for array analysis to proposers. These are expected to be leveraged thru partnership with commercial or near-commercial sources of platforms and arrays.**

5) On pages 8-9, Evaluation Study 4 is not very clear as to populations to be selected. Would you be able to provide an example of the type of chronic infection scenario envisioned.

**Although most infectious agents of interest do not persist in the host resulting in a chronic infection, should a performer choose to evaluate samples from a host with an infectious agent capable of producing chronic infection, we would like to understand the extent to which chronic infection impacts the immune signature of the host. If we are to validate an agent agnostic diagnostic test (one test able to diagnose multiple diseases) there is a need to evaluate samples from each scenarios associated with the infectious agent (acute vs. chronic vs. convalescent vs. vaccinated), if they exist.**

6) Page 23 states the following: Part 3: Full Proposal (Phase 2) Summary of Costs and Related Information Form (See Section 8.4 – Attachment D of this BAA). Please complete this form and

**BAA 14-004 (HSHQDC-14-R-B0008)  
Amendment 1**

provide it as an attachment to the Cost Proposal. Certified cost and/or pricing data may be required. However, there does not appear to be an Attachment D included in the BAA or on FedConnect. Can you please direct us?

**Please use the attached form.**

7) We have a question regarding the spreadsheet. Our Institution calculates overhead expenses on personnel costs. Do we have permission to edit the formulas in the spreadsheet to accommodate our institution's budgeting practices per our federally-approved indirect cost rate agreement?

**Yes.**

All other terms and conditions of the BAA remain unchanged and are in full force and effect.